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T cells can mediate remarkable tumor regressions including complete cure in patients with metastatic cancer.
Genetic alterations in an individual’s cancer cells (the mutanome) encode unique peptides (m-peptides) that can be
targets for T cells. The recent advances in next-generation sequencing and computation prediction allows, for the
first time, the rapid and affordable identification of m-peptides in individual patients. Despite excitement about the
extended spectrum of potential targets in personalized immunotherapy, there is no experience or consensus on
the path to their successful clinical application. Major questions remain, such as whether clinical responses to
cytokine therapy, T cell transfer, and checkpoint blockade are primarily mediated by m-peptide-specific reactivity,
whether m-peptides can be effectively used as vaccines, and which m-peptides are most potently recognized.
These and other technological, immunological and translational questions will be explored during a 1-day
Workshop on Personalized Cancer Immunotherapy by the Society for Immunotherapy of Cancer, directly before the
Annual Meeting, on November 7, 2013 at the National Harbor, MD near Washington, DC.
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The cancer mutanome: is it important?
Peptides encoded by mutated genes in cancer cells have
long been recognized as potential T cell targets, yet they
were not pursued for personalized cancer therapy due
to time and cost constraints on their identification. The
recent arrival of next-generation sequencing and bio-
informatics approaches allows, for the first time, the
rapid and affordable elucidation of an individual cancer
patient’s genome, exome, epigenome and transcriptome
at the single nucleotide level [1]. This in turn enables
the identification of patient-specific omic alterations
that can function as unique therapeutic targets such
as neoantigens [2-8] (Figure 1). The collective of an
individual patient’s tumor-specific alterations and muta-
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reproduction in any medium, provided the orspecific antigens that are different from “shared” anti-
gens, which are expressed in tumors from multiple
patients and are typically normal, non-mutated self-
proteins. In particular, mutanome-encoded peptides
(hereafter called m-peptides) may evoke a more vigor-
ous T cell response due to a lack of thymic tolerance
against them, and this immunity may be restricted
to tumors, since the mutated gene product is only
expressed in tumors [9].
These assumptions have not been rigorously tested,
and our understanding of, for example, m-peptide-spe-
cific peripheral tolerance and T cell cross-reactivity
with wild-type peptides is limited at best. Yet several
very exciting recent reports on the power of immunity
against m-peptides to shrink tumors in mice and pa-
tients suggest the importance of understanding the
biology of m-peptides and their application in immuno-
therapy. For example, a tantalizing possibility is that
the remarkable clinical response rates to adoptively
transferred T cells, and to CTLA-4 and/or PD(L)-1al Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 Highly personalized medicine. Inexpensive and highly available DNA sequencing can revolutionize cancer immunotherapy by
enabling highly personalized approaches involving the identification of new tumor-associated antigens. The expressed genes from a patient’s
tumor can be sequenced to identify candidate mutant T cell epitopes. Relevant epitopes that could potentially bind to any given patient’s HLA
molecules could be predicted using peptide prediction algorithms (e.g. http://www.syfpeithi.de/bin/MHCServer.dll/EpitopePrediction.htm.
Or http://www-bimas.cit.nih.gov/molbio/hla_bind). If peptides derived from mutant proteins are found to capable of forming new HLA-restricted
target structures, the candidate peptides can be used in one of at least several ways: 1) “fish out” or sort cells for relevant antigens (such as those
specific for driver oncogenes) using tetramer like reagents; 2) use the candidate peptides to stimulate T cell clonotypes already present in a
patient’s tumor or in their peripheral blood; 3) use antigens to elicit new T cell receptors in mice that are transgenic for human MHC molecules;
and 4) to immunize patients against antigens. If the T cells generated are specific for a patient’s tumor, they can be expanded and adoptively
transferred if they are of human origin, or used as a source of TCR for gene engineering approaches.
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ily, by m-peptide-specific T cells [10,11]. M-peptide-specific
T cells present before treatment may be a required sub-
strate for successful therapy with cytokines and checkpoint
blockade. Thus, an exciting possibility is that peptide-based
vaccination [12,13] with m-peptides could induce tumor-
specific T cells that are lacking in patients who have failed
to respond to checkpoint blockade, and convert these pa-
tients into responders. M-peptides may also prove to be
major natural targets for tumor-specific TIL [6], and could
be used for ex vivo expansion of patient-derived T cells
(TIL or PBMC) before adoptive T cell therapy. In addition,
m-peptides could be efficiently targeted with TCR-
transduced T cells. Finally, m-peptides may be useful in im-
mune monitoring, to evaluate whether m-peptide-specific
immunity correlates with response or disease recurrence
after immunotherapy. Thus, understanding mutanome-
encoded m-peptides as a target for anti-tumor T cells is a
new frontier for cancer immunotherapy.
Review
Recent studies on mutanome-specific anti-tumor immunity
The systematic study of the mutanome has only just
begun. Importantly, it appears that different cancer types
and histologies harbor different numbers of mutations.
Those with high numbers of mutation include cutaneous
melanoma, smoking-induced lung cancer, and colon
cancer, in particular hypermutators [9,14]. This is likely
related to the high exposure of the respective cells of
origin to mutagenic and inflammatory stimuli: UV light,
cigarette smoke and food-contained mutagenic and in-
flammatory compounds. It is interesting that melanoma
and lung cancer both respond particularly well to PD-1
immunotherapy, possibly implying that m-peptides are
particularly involved in the therapeutic T cell response
to this therapy [15,16].
In mice, methylcholanthrene-induced sarcomas likewise
harbor a large number of mutations, and a subset of these
tumors are particularly immunogenic: they will grow in
immunodeficient but not in immunocompetent mice.
Matsushita et al. analyzed the mutanome of one such im-
munogenic tumor by exome sequencing and MHC binding
algorithms and identified a point mutation in the spectrin-
β2 gene that resulted in an m-peptide with greatly in-
creased MHC Class I binding. This peptide proved to be a
dominant tumor antigen that caused the complete, spon-
taneous, CD8+ T cell-mediated regression of this tumor in
immunocompetent mice [14]. Using a similar approach,
Castle et al. analyzed the mutanome of the widely used
B16 melanoma cell line and tested 50 MHC-binding m-
peptides, 16 of which were immunogenic and 11 of which
preferentially recognized the mutant peptide over the wild-
type counterpart. Importantly, they showed that vaccin-
ation with 2 of those suppressed the growth suppressionof established B16 melanomas [17]. Robbins et al. similarly
studied melanomas from 3 patients who responded to ther-
apy with ex-vivo expanded autologous tumor-infiltrating
lymphocytes (TIL), and identified a total of 7 unique m-
peptides that appeared to be processed and presented by
autologous tumor cells and were recognized by the autolo-
gous TIL [11].
These three studies used exome sequencing and com-
puter algorithm-guided peptide epitope prediction to iden-
tify MHC Class I-binding m-peptides that were processed
and presented by tumor cells and recognized by tumor-
specific T cells, thus validating the approach. However,
other approaches exist, such as the direct elution of pep-
tides from the surface of tumor cells, or even from circulat-
ing tumor-derived HLA complexes, and their subsequent
identification by microcapillary chromatography/tandem
mass spectrometry [18]. In combination with tumor exome
data, or after in silico subtraction of peptides isolated from
normal cells, tumor-expressed m-peptides can be identi-
fied, including peptides that undergo post-translational




With the technology to efficiently mine the mutanome
in a high-throughput fashion only just becoming avail-
able, many questions remain regarding its application in
personalized immunotherapy. Some of these are:
1. What are the possible and most important uses of
m-peptides?
2. Are m-peptides superior to shared/self-peptides as
therapeutic targets for anti-tumor T cells?
3. What fraction of m-peptides is actually processed
and presented in the context of MHC molecules on
tumor cells?
4. What fraction of these peptides evokes a T cell
response in the host (spontaneously or after
vaccination)?
5. How frequently do T cells against m-peptides cross-
react with the corresponding wild-type peptides
expressed on normal cells?
6. Are m-peptides the dominant peptides recognized in
spontaneous tumor-specific immune responses?
7. Can m-peptide-based vaccines induce therapeutic
immune responses, alone or as part of combination
therapies?
8. Are m-peptides the dominant peptides recognized in
therapy-induced immune responses (e.g. checkpoint
blockade, TIL, IL-2, IFN-α, radiation, immunogenic
chemotherapies).
9. What “pipeline” allows the shortest time from fresh
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vs. RNA?
1. What are the best approaches for filtering the
numerous sequencing errors before declaring a
somatic mutation?
2. What peptide prediction algorithms are best at
predicting MHC-binding peptides from exome data?
3. What is the impact of the immunoproteasome,
peptide splicing, and post-translational modification
on the actual expression of predicted m-peptides on
tumor cells?
4. What are safety and regulatory issues in designing
personalized cancer vaccines against never-before
targeted, patient-specific antigens?Conclusions
The 2013 society for immunotherapy of cancer workshop
on personalized immunotherapy
The mining of the mutanome has just begun, and many
questions regarding methodology, application and future
opportunities remain open and ready for debate. With
many groups currently engaging this area, it is a prime time
to come together and share data, viewpoints and best prac-
tices, forge collaborations, and chart a course for the imme-
diate future. The Society for Immunotherapy of Cancer
invites you to attend their Workshop on Personalized Im-
munotherapy, directly before the Annual Meeting, on Nov
7, 2013 at the National Harbor, MD near Washington, DC.
Specifics can be found at the Society website at www.
sitcancer.org/2013/workshop. Abstracts and posters are
welcome through August 26, 2013, and platform presenta-
tions will be selected.
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